Linde Stock Barely Moved While Its Order Book Hit A Record

A record backlog of plants, led by a new electronics win, is the clearest evidence yet of how Linde keeps topping itself up, and of how slowly that shows up in the stock.

Records In The Business, A Flat Year In The Stock

Linde (LIN) stock has returned 4.0% over the past twelve months and lost 4.2% over the past three, while the S&P 500 gained 3.9% over the same three months. It trades about 12% below its 52-week high. The business did not stand still. Sales of $9.3 billion in the second quarter of 2026 rose 9% from a year earlier, helped by a 2% currency tailwind, adjusted earnings per share of $4.50 came in 10% higher, and by the company’s own account both were records.

A Billion Dollars Of New Plants Landed In One Quarter

The order book behind that quarter matters more. Linde’s sale-of-gas backlog ended the first quarter of 2026 at $7.1 billion. Three months later it stood at a record $8.1 billion, after the company added $1 billion of electronics wins to serve advanced node fabs in the Western US. The plants are already going up, not a forecast.

Electronics is the engine. On the company’s own end-market breakdown, electronics grew 10% year over year in the first quarter of 2026 and 18% in the second, and management expects it to remain the largest contributor to the backlog for the foreseeable future. The record figure does not capture everything: electronics wins at a joint venture, carrying roughly $800 million of investment, sit outside the backlog altogether.

Does A Record Backlog Actually Turn Into Earnings?

Slowly, and that is the point. Backlog projects take two to three years to build and then ramp, and each cleared a post-tax, unlevered double-digit return hurdle before the capital was committed. Size it honestly, because a backlog is capital to be spent, not revenue booked. Management’s own conversion range is 20% to 50% of that capital in annual sales, which puts roughly $1.6 billion to $4 billion of eventual annual revenue against the $34.66 billion this global industrial gases and engineering company already books over the trailing twelve months. That is a compounder topping itself up, not a re-rating.

And it refills about as fast as it drains. Management expects to start up more than 20 projects worth about $1.3 billion of investment over the rest of 2026 and still finish the year with the backlog starting with an eight. What it cannot yet promise is that profit follows on the same schedule.

The Margin Line Is Where This Case Gets Tested

Compared with its own recent history, Linde is improving. Revenue is growing 5.0% year over year against a three-year average pace of 1.3%, and operating margin over the trailing twelve months, at 27%, sits at its own three-year peak, above a three-year average of 26%.

The quarter just reported went the other way. Operating margin excluding cost pass-through fell about 30 basis points from a year earlier, driven by the US homecare business; on the same measure, the Americas excluding that unit would have been up 20 basis points. Management says it is not satisfied, has actions running for sequential improvement into the third quarter of 2026, and is evaluating whether that business belongs in the portfolio at all.

So What Has To Happen Before The Backlog Pays

The margin line has to hold. The upside case is real, but it is a compounding case rather than a moonshot: Linde has cleared a 30% gain in under two months only once since 2020, and nothing in the order book changes that shape. What settles the pace is the sequential improvement management expects in the third quarter of 2026, sitting behind a full-year 2026 earnings guide whose bottom already moved from $17.60 to $17.70 while the top stayed at $17.90. Deliver that improvement and the backlog is being paid for on schedule; miss and a record order book is only a longer wait. That is why it is worth keeping a screen open on companies whose own guidance keeps grinding higher.

A Compounder Can Still Sit Out A Year

If you already own Linde, you have just watched the business set records while the stock went roughly nowhere, and that gap is what a long-cycle order book does to a shareholder’s patience. If you are still deciding, you are underwriting plants that will not run for two to three years. Either way, a single company’s execution schedule carries the whole result. A rules-based system that spreads the bet across many names and acts on evidence rather than patience is a different machine, and the Trefis High Quality portfolio is built to be exactly that. That portfolio has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.